Shuchleib R

Idioma: Español
Referencias bibliográficas: 26
Paginas: 38-41
Archivo PDF: 64.37 Kb.

RESUMEN

A dos años de su introducción en la terapéutica, los inhibidores de la ciclooxigenasa (COXIB) y en particular los específicos sobre COX-2 han sido ampliamente utilizados para el control del dolor y la inflamación en padecimientos crónicos como son las enfermedades reumáticas más comunes, la osteoartritis y la artritis reumatoide; y en situaciones agudas, como analgésicos en padecimientos diversos, además de los reumáticos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Desai MM, Zhang P, Hennessy CH. Surveillance for morbidity and mortality among older adults. United States, 1995-1996. MMWR CDC Surveill Summ 1999; 48:7-25

2. Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and Selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 788- 799.

3. Bori-Segura G. Principales enfermedades reumáticas en México. Aspectos epidemiológicos e impacto socioeconómico. Rev Mex Reumat 2000; 15(6): 183-201.

4. Black HR. Isolated systolic hipertension in the elderly: lessons from clinical trials and future directions. J Hipertens 1999; 17 (Suppl 5): S49-S54.

5. Izzo JL Jr, Levy D, Black HR. Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35: 1021-1024.

6. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90: 42S-47S.

7. Pope JE, Anderson JJ, Felson DT. A meta-analyses of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 447-484.

8. Morgan T, Anderson A. Interaction of indomethacin with felodipine and enalapril. J Hypertens 1993; 11: S338.

9. Vane JR. Inhibition of prostaglandin Synthesis as a mechanism of action for aspirin-Like drugs. Nature 1971; 231(25): 232-235.

10. O’Neill GP, Ford-Hutchinson AW. Expression of mesenger mRNA for Cyclooxygenase-1 and cyclooxygenase-2 in human tissues FEBS Lett. 1993; 330: 156-160.

11. Kargman S, Charleson S, Cartwrigth M et al. Characterization of prostaglandin G/H Synthase 1 and 2 in rat, monkey and human gastrointestinal tracts. Gastroenterology 1996: 91; 111: 445-454.

12. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997; 24 Suppl. 49: 6-8.

13. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-12017.

14. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2 selective inhibition. Am J Med 1999; 107: 65S-10S.

15. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial, Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.

16. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib an naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520- 1528.

17. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2 Specific inhibitors and cardiorenal function: A Randomized, controlled trial of Celecoxib and Rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.

18. Oates JA, Fitzgerald GA, Branch RA et al. Clinical implications of prostaglandin and Thromboxane A2 formation. N Engl J Med 1988: 319: 761.

19. Patrono C, Dunn MJ. The Clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1.

20. Johnson AG, Nguyen TV, Owe-Young R. Potential mechanism by which nonsteroidal anti-inflammatory drugs elevate bood pressure: The role of endothelin-1. J Hum Hypertens 1996; 10: 257.

21. Antiplatelet trialists collaboration. BMJ 1994; 308: 235-348.

22. Swan SK, Rudy DW, Lasseter KC et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.

23. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 14665-1470.

24. Vioxx® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., March 2000

25. Celebrex® [package insert]. Skokie, IL: Searle & Co., Inc., December 1999.

26. Whelton A, Maurath CJ, Verburg KM et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000; 7: 159-176.